Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation

Transplantation Proceedings

Volumn 47, Issue 2, 2015, Pages 478-484

  Singer, G A ^a   Zielsdorf, S ^a   Fleetwood, V A ^a   Alvey, N ^a   Cohen, E ^a   Eswaran, S ^a   Shah, N ^a   Chan, E Y ^a   Hertl, M ^a   Fayek, S A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BASILIXIMAB; BILIRUBIN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOTIDE DERIVATIVE; TACROLIMUS; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; GUANINE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DNA VIRUS; DRUG APPROVAL; DRUG COST; DRUG SAFETY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT FAILURE; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GRAFT SURVIVAL; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84926179043     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.11.029     Document Type: Article

References (25)

1. D. Samuel, A. Bismuth, and D. Mathieu Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients Lancet 337 1991 813 815
2. D. Samuel, R. Muller, and G. Alexander Liver transplantation in European patients with the hepatitis B surface antigen N Engl J Med 329 1993 1842 1847
3. R.G. Sawyer, R.W. McGory, and M.J. Gaffey Improved clinical out- comes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization Ann Surg 227 1998 841 850
4. R.J. Fontana, E.B. Keefe, and S. Han Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients [abstract] Hepatology 30 suppl 1999 301A
5. G.V. Papatheodoridis, V. Sevastianos, and A.K. Burroughs Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era Am J Transplant 3 2003 250 258
6. G.V. Papatheodoridis, M. Buti, and M. Cornberg EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
7. M.A. Huang, and A.S. Lok Natural history of hepatitis B and outcomes after liver transplantation Clin Liver Dis 7 2003 521 536
8. G.V. Papatheodoridis, E. Cholongitas, A.J. Archimandritis, and A.K. Burroughs Current management of hepatitis B virus infection before and after liver transplantation Liver Int 29 2009 1294 1305
9. E. Cholongitas, J. Goulis, E. Akriviadis, and G.V. Papatheodoridis Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review Liver Transpl 17 2011 1176 1190
10. Z.F. Xi, Q. Xia, and J.J. Zhang The role of entecavir in preventing hepatitis B recurrence after liver transplantation J Dig Dis 10 2009 321 327
11. L. Teperman, J. Spivey, and F. Poordad Emtricitabine/tenofovir DF combination +/- HBIG post orthopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results [abstract] J Hepatol 52 suppl 2010 12 13
12. B. Degertekin, S.H. Han, and E.B. Keeffe Impact of virologic breakthrough and HBIG regimen on Hepatitis B recurrence after liver transplantation Am J Transplant 10 2010 1823 1833
13. M. Jiménez-Pérez, A.B. Sáez-Gómez, and L. Mongil Poce Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant [abstract] Transplant Proc 42 suppl 2010 3167 3168
14. M. Ishigami, Y. Onishi, and T. Ito Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients Hepatol Res 41 2011 1189 1198
15. C.J. Cai, M.Q. Lu, and Y.H. Chen Clinical study on prevention of HBV re-infection by entecavir after liver transplantation Clin Transplant 26 2012 208 215
16. R. Perrillo, M. Buti, and F. Durand Safety and efficacy of entecavir in patients receiving liver transplantation due to chronic hepatitis B [abstract] J Hepatol 56 suppl 2012 212
17. T.H. Hu, C.L. Chen, and C.C. Wang Pre-transplant HBV viral resistance is not a risk factor for HBV recurrence after liver transplantation [abstract] Liver Transpl 18 suppl 2012 174
18. Y. Ueda, H. Marusawa, and T. Kaido Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation Hepatol Res 43 2013 67 71
19. E. Cholongitas, T. Vasiliadis, and N. Antoniadis Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation Transpl Infect Dis 14 2012 479 487
20. US Department of Health and Human Services/Organ Procurement and Transplantation Network. Center Data. http://optn.transplant.hrsa.gov/latestData/stateData.asp?type=center. Accessed February 2014.
21. US Food and Drug Administration. HepGamB Prescribing Information. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm119010.pdf. Accessed February 2014.
22. Centers for Medicare and Medicaid Services. Fee Schedule. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed February 2014.
23. I. Campos-Varela, L. Castells, and M. Buti Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? Ann Hepatol 10 2011 180 187
24. S. Saab, S. Desai, and D. Tsaoi Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy Am J Transplant 11 2011 511 517
25. E.F. Ellis, and C.S. Henney Adverse reactions following administration of human gamma globulin J Allergy 43 1969 45 54